JAN 31, 2019 12:00 PM PST

Development of Recombinant Transgenic Proteins to Probe Cellular Signaling Mechanisms in Preclinical Drug Target Discovery and Drug Development

Presented at: BioProcessing 2019
Speaker
  • Professor & Felix and Carmen Sabates Missouri Endowed Chair in Vision Research, Departments of Ophthalmology & Biomedical Sciences, University of Missouri - Kansas City, School of Medicine
    Biography
      Peter Koulen, PhD, FARVO, is a Professor of Ophthalmology and Biomedical Sciences and the Felix and Carmen Sabates Missouri Endowed Chair in Vision Research at University of Missouri- Kansas City School of Medicine. Dr. Koulen also serves as Director of Basic Research at UMKC's Vision Research Center. His research includes optical imaging, electrophysiology and biochemistry to elucidate mechanisms underlying basic physiology and pathophysiological processes at the molecular, cell and system levels. Dr. Koulen was trained at the Max-Planck-Institute for Brain Research in Frankfurt, Germany and at the Johannes Gutenberg - University, Mainz, Germany, followed by post-doctoral fellowships at Yale University School of Medicine and the Marine Biological Laboratory Woods Hole, MA. He is a regular presenter at scientific meetings, author of over 100 peer-reviewed articles in biomedical research and is a reviewer and editorial board member for a range of scientific journals. Dr. Koulen serves as a reviewer for national and international as well as private and governmental funding agencies.

    Abstract

    A range of cellular signaling mechanisms are controlled by highly specific protein-protein binding, which controls both protein function and protein distribution. The presentation focuses on the use of two complementary approaches to interrogate these mechanisms at the protein and cellular levels, the expression of recombinant proteins and protein binding domains using bacterial protein expression for biochemical studies and using mammalian protein expression for cell biology studies. Examples from neuroscience and ion channel physiology are being discussed and utilized to illustrate the impact of transgenic approaches when integrated with functional assays. In addition, the presentation includes clinical rationales for experimental design underlying the development of recombinant transgenic proteins and protein fragments to probe cellular signaling mechanisms. Conversely, the impact of the identification of such mechanism on preclinical research and subsequent therapy development is being discussed. 


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 05, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 05, 2020 7:00 AM PST
    DATE: Date needed, 2020 TIME: Time needed Exosomes are a population of naturally occurring mobile, membrane-limited, 30 – 100 nm in diameter, extracellular vesicles containing a large...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    JAN 31, 2019 12:00 PM PST

    Development of Recombinant Transgenic Proteins to Probe Cellular Signaling Mechanisms in Preclinical Drug Target Discovery and Drug Development

    Presented at: BioProcessing 2019

    No demographic data is available yet for this event.


    Show Resources
    Loading Comments...
    Show Resources